



Medicine Adaptive Pathways to Patients: why, when and how to engage?

(Abstract – Manuscript in preparation)

November 2017

The work leading to these results was conducted as part of the ADAPT SMART consortium (Accelerated Development of Appropriate Patient Therapies: a Sustainable, Multi-stakeholder Approach from Research to Treatment-outcomes). For further information please refer to www.adaptsmart.eu. This paper only reflects the views of the authors.

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115890. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.



Abstract

MAPPs seek to address the ‘evidence versus access’ conundrum faced by patients, healthcare professionals, healthcare decision makers and pharmaceutical innovators. The conundrum refers to the delicate trade-offs between ensuring rapid access to promising treatments for patients in urgent need on the one hand and ensuring that patients, healthcare professionals and other decision-makers possess adequate information on benefits and risks at the time of launch on the other hand. The MAPPs concept is not an official designation and is not intending to create new regulatory or legal frameworks. It instead aims to make better use of various existing tools and procedures for medicines development, marketing authorisation, reimbursement, on-market clinical use and monitoring of benefits and harms. We here summarise the MAPPs engagement process and critical questions to be asked at each milestone of the product life-span.